AGIO vs ESTA
AGIO: Agios Pharmaceuticals is a rare disease-focused biopharmaceutical company advancing a pipeline of novel hematology and genetic disorder therapies, anchored by its pyruvate kinase activator, mitapivat. ESTA: Establishment Labs is a medical technology company transforming breast aesthetics and reconstruction with its innovative, safety-focused Motiva implant platform and minimally invasive surgical solutions.
Side-by-side fundamentals
| Metric | AGIO | ESTA | Edge |
|---|---|---|---|
| Price as of 2026-10-30 close | $30.55 | $62.46 | |
| Market cap | $1.8B | $1.9B | |
| Net margin FY2025, SEC XBRL | -764.0% | -24.2% | ESTA higher |
| Gross margin FY2025, SEC XBRL | n/a | +69.3% | |
| Operating margin FY2025, SEC XBRL | -873.9% | -18.5% | ESTA higher |
| ROE FY2025, SEC XBRL | -34.6% | -216.9% | AGIO higher |
| ROA FY2025, SEC XBRL | -31.8% | -14.3% | ESTA higher |
| Debt / equity | 0.00 | 12.11 | AGIO lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +48.0% | +27.1% | AGIO higher |
| Revenue CAGR (3y) SEC XBRL | +56.0% | +9.3% | AGIO higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.09 | 1.77 | |
| 1-year return as of 2026-10-30 close | -29.2% | +22.7% | ESTA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.